NF-kappa-B activation unveils the presence of inflammatory hotspots in human gut xenografts

Einat Nissim-Eliraz1*, Eilam Nir1*, Noga Marsiano1, Simcha Yagel2, Nahum Y. Shpigel1*  
1 Department of Basic Sciences, Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel, 2 Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel  
* These authors contributed equally to this work.  
* nahum.shpigel@mail.huji.ac.il

Abstract

The single-epithelial cell layer of the gut mucosa serves as an essential barrier between the host and luminal microflora and plays a major role in innate immunity against invading pathogens. Nuclear factor kB (NF-κB), a central component of the cellular signaling machinery, regulates immune response and inflammation. NF-κB proteins are activated by signaling pathways downstream to microbial recognition receptors and cytokines receptors. Highly regulated NF-κB activity in intestinal epithelial cells (IEC) is essential for normal gut homeostasis; dysregulated activity has been linked to a number of disease states, including inflammatory bowel diseases (IBD) such as Crohn’s Disease (CD). Our aim was to visualize and quantify spatial and temporal dynamics of NF-κB activity in steady state and inflamed human gut. Lentivirus technology was used to transduce the IEC of human gut xenografts in SCID mice with a NF-κB luminescence reporter system. NF-κB signaling was visualized and quantified using low resolution, intravital imaging of the whole body and high resolution, immunofluorescence microscopic imaging of the tissues. We show that NF-κB is activated in select subset of IEC with low “leaky” NF-κB activity. These unique inflammatory epithelial cells are clustered in the gut into discrete hotspots of NF-κB activity that are visible in steady state and selectively activated by systemic LPS and human TNFα or luminal bacteria. The presence of inflammatory hotspots in the normal and inflamed gut might explain the patchy mucosal lesions characterizing CD and thus could have important implications for diagnosis and therapy.

Introduction

Understanding mucosal immunity is critical for filling the knowledge gaps in the pathogenesis of inflammatory human gut disease such as Crohn’s Disease (CD).

Most patients with Crohn’s disease have focal mucosal inflammation scattered throughout extensive portions of an otherwise normal bowel. It is assumed that gut inflammation occurs topographically at random and that the immune response potency is uniform within a region. The nuclear factor kappa B (NF-κB) family of transcription factors plays a central role in
coordinating the expression of genes that control inflammation, immune responses, and a variety of other biological processes [1]. NF-κB plays a central role in IBD development and progression, and the level of activation of NF-κB correlates with the severity of intestinal inflammation [2]. Intestinal epithelial cells (IEC) are critical elements of gut homeostasis and function. Mikuda et al. recently demonstrated that in IEC the intrinsic dual and seemingly opposing, anti- and pro-inflammatory activities of NF-κB are critical for normal gut homeostasis [3]. Furthermore, these authors showed that dysregulated constitutive activity of NF-κB in IEC led to epithelial dysfunctions, barrier disruption and mucosal inflammation, all of which are known hallmarks of IBD.

Recent in vitro live-single cell analysis of NF-κB activity revealed important molecular and mechanistic cues underlying the regulation of NF-κB [4,5]. These authors and others showed that activation of NF-κB in a seemingly uniform population of cells is highly heterogeneous and that cells are actually protected against harmful homogenous cellular activation [6]. Moreover, it was demonstrated that steady state cells with “leaky” NF-κB activity were high responders to various insults [5]. Although understanding NF-κB activity in complex multicellular organs like the gut is a much more ambitious endeavor, some of these insights might help us to better understand the in vivo observations described here.

We have examined the activation of NF-κB in segments of human fetal gut transplanted and developing in a subcutaneous, sterile environment in SCID mice. The experimental model system we have used was first reported by Winter et al. in 1991 [7] and refined in our laboratories for study of the human enteric nervous system [8], human-specific pathogens [9,10] and inflammatory bowel diseases (IBD) [11–13]. Fetal gut was obtained after informed consent from pregnancy terminations performed legally at 12–18 weeks gestational age and transplanted subcutaneously in mature SCID mice. The human gut tissue vascularizes, expands and persists as a human gut implant, and can be experimentally manipulated over the course of the subsequent several months. While ectopic and not functional, these gut implants develop characteristic structures of the human gut with extensive vasculature and their structural features are highly similar to those of normal human gut, including mucosal villous epithelium, crypt structures, blood vessels and enteric nervous system.

We and others have previously shown that virtually all the cell types that are present in the normal human gut are also present in these xenografts [8–10,13–16]. Moreover, the general architecture of the gut appears normal, and the tissue is well-vascularized by a human capillary system that anastomoses to the circulatory system of the murine host. In this, the experimental platform is similar to other examples of development of human tissues (lung, skin and liver) subcutaneously transplanted into SCID mice [17,18]. Furthermore, we have shown that many human innate and adaptive components of immune system, which have been shown to be already active in fetal gut at the time of transplantation [19–23], are present and active in the mature xenograft [12,13].

The model system allows the study of human immune activation in an animal model and is especially suited to the investigation of this response in mucosal epithelial of the gut. The intestinal epithelium is a single layer of cells with rapid turnover requiring constant tissue replenishment fueled by continuously dividing stem cells that reside at the bottom of crypts. These cells continuously proliferate and give rise to progenitor cells that differentiate to one of six different mature cell types and move upwards towards the villous, where they are shed into the intestinal lumen after 3–5 days [24]. Henceforth, transduction of gut epithelium with a stable reporter gene requires infection of crypt stem cells and integration of the transgenes into their genome, all other transduced cells will undergo apoptosis and slough into the lumen.

HIV-derived lentiviral vectors (LVs) integrate into the target cell chromatin and are maintained as cells divide, a potential advantage for establishing long-term expression of reporter
transgenes. We have developedLVs that achieve stable transgene expression in mucosal epithelial cells of human fetal gut xenografts.

We monitoredNF-κB dynamics by low resolution time-lapse bioluminescence imaging of human gut xenografts expressing a short-lived luciferase reporter gene controlled by NF-κB response elements.

Materials and methods

SCID mouse human intestinal xeno-transplant models

This model system was extensively described by us [8–14]. C.B-17/IcrHsd-Prkdcscid (abbreviated as SCID) mice were purchased from Harlan Biotech Israel (Rehovot, Israel). All mice were housed in a pathogen-free facility, in individually ventilated cages (IVC), given autoclaved food and water. All animal use was in accordance with the guidelines and approval of the Animal Care and Use Committee (IACUC) of the Hebrew University of Jerusalem. IRB and IACUC approvals were obtained prospectively (Ethics Committee for Animal Experimentation, Hebrew University of Jerusalem; MD-11-12692-4 and the Helsinki Committee of the Hadassah University Hospital; 81-23/04/04).

Euthanasia was performed by appropriately trained personnel approved on the Animal Protocol. All euthanasia procedures were continuously monitored by the person(s) performing the procedure with verification at the end of the procedure.

The person who conducted the procedure ensured that the animal is euthanized in a competent and humane way. One animal was euthanized at a time, by using continuous flow of CO2 at flow rate of 3 L/minute (30% of the chamber volume per minute) and continued for one minute after breathing stopped.

All animal procedures were performed by personnel trained to recognize, assess and monitor pain, suffering and distress as well as detecting positive welfare.

All animal procedures described in this study were performed as approved on Animal Protocol.

Women undergoing legal terminations of pregnancy gave written, informed consent for use of fetal tissue in this study.

Human fetal small bowel 12–18 weeks gestational age was implanted subcutaneously on the dorsum of the mouse as described previously [9,10]. All surgical procedures were performed in an aseptic working environment in a laminar flow HEPA-filtered hood with isoflurane inhalation anesthesia (1.5 to 2% v/v isoflurane in O2). Before surgery, carprofen (5 mg/kg, Rimadyl, Pfizer Animal health) was administered subcutaneously. The surgical area was shaved and depilated (Nair hair removal cream) and the skin was scrubbed and disinfected with betadine and 70% (v/v) ethanol. After surgery the mice were provided with enrofloxacin-mediated water (Bayer Animal HealthCare AG) for 7 days and were closely monitored once a day for behavior, reactivity, appearance and defecation. Grafts developed in situ for 12–16 weeks prior to manipulation.

Activation of inflammation

We used LPS (from E. coli serotype O55:B5, Sigma, Rehovot, Israel) or human TNFα (Peprotech) by intraperitoneal injection or intraluminal bacterial infection to induce inflammatory response in the implant in SCID mice with mature human gut xenograft. Transplanted mice were subjected to systemic LPS (0.1, 1 or 10 mg/kg) or human TNFα (1 mg/kg), well-established models of experimental sepsis and inflammatory gut disease [25–29]. Enteropathogenic E. coli (EPEC) bacteria, serotype O127:H6 strain E2348/69 (Nataro & Kaper, 1998), were used in this study. Bacteria were grown in Luria-Bertani (LB) broth at 27°C. For in vivo challenge
studies, cultures were diluted to $10^7$ CFUs in 100 μl culture medium and injected into the lumen of the human gut xenografts.

**Plasmids and recombinant viruses**

To create lentiviral NF-κB reporter vectors, two target plasmids (transfer vectors) were constructed to express a low resolution luminescence reporter and a high resolution fluorescence reporter. The luminescence reporter was constructed of destabilized firefly luciferase (pGL4.24-luc2P, Promega) [30,31] open reading frame controlled by a DNA cassette containing five tandem repeats of the NF-κB transcriptional response element (pLNT-minP-5κB-luc2P) [32]. The fluorescence reporter was constructed of human p65 N-terminal fusion with tagRFP reporter (pLNT-UbC-tagRFP-p65). The lentiviruses were produced from HEK293FT cells (ThermoFisher scientific) through co-transfecting the target plasmid pLNT and the packaging vectors pMDLg-RRE, pRSV-REV and pCMV-VSVG as previously described [33]. Co-transfection using VSVG plasmid encoding for envelope G glycoprotein from VSV, produced pseudotyped retrovirus which depends on the expression of Low density lipoprotein receptor (LDLR) on plasma membrane for the infection of target cells [34–36]. Lentiviruses were purified by ultracentrifugation and then quantitated.

**In vitro lentivirus target validation (S1 and S2 Figs)**

The lentivirus target and reporter system were validated in mouse and human tissue cultured cell lines [37]. Mouse RAW 264.7 and human THP-1 macrophage-like cell lines, mouse mammary epithelial line EPH4 and human embryonic cell line HEK293FT were infected with the lentiviral NF-κB reporter vector. RAW 264.7 and THP-1 cells were cultured and activated by LPS as previously reported [38].

EPH4 and HEK293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) (Biological Industries) and 100 units/ml penicillin, 0.1 mg/ml streptomycin (Pen-Strep; Biological Industries), 1% L-Glutamine (BI) and 1% HEPES buffer (BI) at 37˚C with 5% CO₂. EPH4 and HEK293T cells were infected with the following strains of Enteropathogenic *E. coli* (EPEC); EPEC wild-type E2348/69, E2348/69ΔescV::kan, E2348/69ΔE6::cm, ΔPP4::kan and E2348/69ΔnleBCDE (kindly donated by I. Rosenshine, Hebrew University) [39]. Bacteria were grown in Luria-Bertani (LB) broth at 27˚C. For in vitro challenge studies, bacterial cultures were diluted in cell culture medium to multiplicity of infection (MOI) of 1. Cells were plated at equal density and luminescence signals were quantified in the presence of 150 μg/ml D-luciferin (GoldBio) by imaging using cooled CCD optical macroscopic imaging system (IVIS Lumina Series III, PerkinElmer Inc., MA USA) and SpectraMax i3x multiple detection microplate reader (Molecular Devices, CA USA).

Fluorescence in situ hybridization (FISH) was performed using Stellaris RNA FISH (LGC Biosearch Technologies, Petaluma, CA) as previously described [40]. A set of Quasar 670-labeled oligonucleotide probes were designed to selectively bind to luc2P transcripts. EPH4 cells transduced with pLNV-minP-5kB-luc2P were grown on 12 mm glass coverslips in 24-well plates at a density of 3x10^5 cells/well. The next day, cells were treated with 10 μg/ml *Mycoplasma bovis* lipopolysaccharides for 2hr at 37˚C. *Mycoplasma bovis* strain 161791 [41] lipopolysaccharides were prepared using Triton X-114 phase fractionation method as previously described [42]. Hybridizations were done according to manufacturer protocol for adherent cells, using commercial hybridization buffer and wash buffers, 4,6-diamidino-2-phenylindole (DAPI) dye for nuclear staining was added during the washes. Images were taken with epifluorescence microscopy system (Axio Imager M1, Zeiss, Germany).
**Lentivirus injection**

Intra-xenograft viral injections were performed in mature gut xenografts 12–16 weeks after transplant. Mice were prepared and anesthetized as described above, using 27 gauge beveled needle the virus was injected directly into the wall of the gut xenograft through the skin above the transplant. Each xenograft received 10X15 μl injections of lentivirus applied along the long axis of the dorsal wall.

**Real-time PCR for analyses of Luciferase gene copy number in human gut xenografts**

Total genomic DNA was extracted from the focus as well as quiescent regions of the transduced xenograft using DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. To estimate the copy number of the Luc2p gene in the samples, 100 ng genomic DNA was added to the FAST qPCR Universal Master Mix (Kappa Biosystems, Boston, MA, USA) with Luc2p specific primers 5'-TGCAAAGATCCTCAACGTG-3' (forward) and 5'-AA TGGGAAGTCACGAAAGGTG-3'(reverse) and quantitative real-time RT–PCR was conducted on a StepOne Plus PCR instrument (Applied Biosystems). The NF-κB-luciferase (Luc2p) reporter construct plasmid used for standard curve generation was diluted with genomic DNA from untransduced xenograft to control for any inhibitory effect of genomic DNA on PCR. The number of vector DNA molecules in transduced cells was calculated by comparing threshold cycle (Ct) values of samples to that of the plasmid standard curve. For determining the final DNA titer of vectors, the total number of vector DNA molecules in transduced xenografts was normalized to the number of genomes determined by the PTBP2 gene previously described [43].

**Bioluminescence and fluorescence Imaging**

For in vivo imaging, mice were anesthetized and given D-luciferin by IP (150 mg/kg) and whole body imaging was performed using IVIS Lumina Series III (PerkinElmer Inc., MA USA) [44]. As previously described [45], all images were analyzed using Living Image software (version 4.4, Caliper LifeSciences (MA, USA) and the optical signal intensity was expressed as photon flux in units of photons/s/cm²/steradian. Each image was displayed as a false-color photon-count image superimposed on a grayscale anatomic image. To quantify the measured light, regions of interest (ROI) were defined over the subcutaneous human gut xenografts. All values were examined from an equal ROI.

**Histochemical analysis**

As we have previously described [14], mice were killed at the indicated time points after challenge and xenograft tissues were trisected for histology and fluorescence staining. Samples for histological analysis were fixed in neutral buffered 4% paraformaldehyde (PFA), paraffin embedded, and sections were cut at a thickness of 5 μm and stained with hematoxylin and eosin (H&E). Fresh xenograft tissue for fluorescence staining was fixed in 2.5% PFA overnight at room temperature, incubated with 15% (w/v) sucrose for 12 hours at 4°C and frozen in Tissue-Tek® (EMS, Hatfield, PA) embedding medium. Serial 10 μm cryosections were stained with phalloidin (Sigma) and 4’, 6’-diamidino-2-phenylindole (DAPI) (Sigma). For immunofluorescence staining primary antibodies were anti-luciferase antibody (ab21176 Abcam, Cambridge, UK) and alexa fluor 594 Donkey anti rabbit (A21207 Invitrogen, Carlsbad, CA) were used as secondary antibodies. Sections were mounted with VectaShield (Vector Laboratories, Burlingame, CA) and imaged with an Axio Imager M1 upright light microscope (Zeiss, Germany) coupled to a MR3 CCD camera system (ZEN 2012).
Quantitative RT-PCR for analysis of LDLR and PCSK9

Low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes expression in human gut xenografts was analyzed using QPCR as previously described [13,14]. Briefly, total RNA was isolated from xenograft tissue using the GeneElute Mammalian Total RNA Miniprep Kit (Sigma, Rehovot, Israel) combined with on-Column DNase I Digestion Set (Sigma). Reverse transcription was performed using qScript cDNA Synthesis Kit (Quanta biosciences, Gaithersberg, MD, USA) and cDNA was used for subsequent real-time PCR reactions. Quantitative real-time RT–PCR was conducted on a StepOne Plus PCR instrument (Applied Biosystems) using the FAST qPCR Universal Master Mix (Kappa Biosystems, Boston, MA, USA). Primer pairs were: LDLR FORW—5' GTCTTGGCACTGGATCTCGT, and LDLR REV—5' CTGGAAATTGCGCTGGAC; PCSK9 FORW—5' AGGGGAGGACAAGGGGAAGACA TCATTGGGT, and PCSK9 REV—5' CAGGTGGGGGTACGTACC. All reactions were performed in triplicate, and the gene expression levels for each amplicon were calculated using the 2^ΔΔCT threshold cycle (CT) method [46], and the levels were normalized against those for human β2-microglobulin (B2M) mRNA. Melting curve analysis was performed with each primer set to confirm amplification of a single product, and all amplicons were sequenced to ensure reaction specificity.

Results

LDLR expression in human gut xenografts

Our initial attempts to efficiently infect and transduce cells in human fetal gut or fully developed xenografts by injection of lentivirus into the lumen or directly into the gut wall failed. Transduction of human fetal gut cells prior to transplantation was a rare event and difficult to locate using fluorescence microscopic imaging of cryosections. Nevertheless, these rare events clearly demonstrated that the heritable genetic marker p65-RFP was integrated into crypt stem cells via lentiviral vector infection, and that all other cells if at all transduced by the lentivirus vector were normally turned over and lost in the course of xenograft development over a 12 week period. The transduced stem cells in which the p65-RFP transgene have been integrated generated progeny that produce the p65-RFP protein. These cells extend from the crypt base to the villus tip and can be visualized as ribbons of red fluorescing cells (S3 Fig). In attempt to improve the efficiency of lentivirus virus infection and cell transduction we analysed the expression of LDLR expression in human fetal gut and fully developed xenografts. LDLR was previously reported to serve as the major entry port of VSV-G–pseudotyped lentiviral vectors in human and mouse cells [34–36,47]. Furthermore, it was also demonstrate that LDLR is present in gut mucosal epithelial cells and localized to the basolateral membrane [48–51]. Thus, we have used QPCR to analyze the expression of LDLR in the mature human gut xenograft. Surprisingly, the expression of LDLR in mature human gut xenografts was very low in steady state (Fig 1A and 1B). This dearth of LDLR expression in mature human gut xenografts and the lack of expression on the apical membrane of the enterocytes probably explain our failure to infect and transduce these cells.

In vitro and in vivo studies demonstrated increased gene expression and protein production of LDLR by LPS and inflammatory cytokines in many cell types [52,53]. Furthermore, a recent study established the significant role of LDLR as LPS scavenger in sepsis animal models and clinical situations [54]. More importantly, this study also demonstrated the inhibitory effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) on LPS scavenging and clearance in sepsis. PCSK9, a serum protein which is also increased by LPS and in sepsis, binds to LDLR stimulates its internalization, promotes LDLR lysosomal degradation, and prevents recycling.
of LDLR to the cell surface. Thus we hypothesize that LPS might increase cells surface density of LDLR in the human gut xenografts, albeit, this effect might be negated by increased human and mouse PCSK9 which are cross reactive. To test this hypothesis, we administered LPS intraperitoneally (IP) to SCID mice with mature human gut xenografts to measure the expression of LDLR and PCSK9. We have found that systemic administration of LPS to the host mouse resulted in significant increase of LDLR expression in the mature human gut xenografts and decreased expression of PCSK9 expression (Fig 1A). Consequently, we established our working protocol where lentivirus carrying luciferase gene under the control of 5 copies of the NF-κB response element (NF-κB/RE-luciferase reporter; Supplementary Information, S2A Fig) was injected into the wall of fully-developed human gut xenografts 4–6 hours after administration of systemic low dose of LPS (0.1 mg/kg; Fig 1B) to the host mouse.

**Intravital imaging of NF-κB activity in the human gut**

Human fetal gut segments were transplanted subcutaneously in SCID mice and allowed to develop over 12–16 weeks thereafter. Expression of LDLR was activated in fully developed transplants by treating the host mouse with intraperitoneal (IP) injection of 0.1 mg/kg LPS and Lentivirus (NF-κB/RE-luciferase reporter) was injected into the human gut wall 4–6 hours thereafter. Mice were allowed to recover and 2–3 weeks thereafter were subjected to intravital whole body bioluminescence imaging before and after systemic IP injection of LPS (Fig 2) or human TNFα (Fig 3) and intraluminal challenge with wildtype (WT) or T3SS-defective mutant enteropathogenic E. coli (EPEC) bacteria (Fig 4). We have previously demonstrated activation of acute inflammation in human gut xenografts following systemic LPS [13] or intraluminal EPEC infection [14]. While the tacit assumption is that gut inflammation is homogeneous, we surprisingly observed one to two foci of luminescence activity in all xenografts following challenge with similar time course for LPS and TNFα and somewhat longer activity following luminal bacterial challenge. In some xenografts focal activity was detected even before challenge (Figs 3A and 4B) and these steady state foci were further activated following challenge.

Activated xenografts were harvested and luciferase expression was further analyzed using immunofluorescence microscopy (Figs 3D, 3E, 4C and 4D). Luciferase was only detected in foci of luminescence activity and was limited to mucosal epithelial cells of the human gut.
The unexpected observation of focal NF-κB activity in steady state and inflamed human gut might represent foci of higher lentivirus infection and transduction efficiency. To address this possibility we established a real-time quantitative PCR system for analyses of luciferase gene copy number in the human gut xenografts (Fig 5). Our analysis clearly showed that foci of NF-κB activity were not associated with high copy number of luminescence reporter. Viral infection and reporter gene transduction were homogeneously distributed along the human gut xenografts thus verifying that NF-κB activity in mucosal epithelial cells of steady state and inflamed human gut is focal.

Fig 2. Spatial and temporal activity of NF-kappa-B in steady state and inflamed human gut activated by systemic LPS. Human fetal gut was transplanted into SCID mouse and allowed to develop over 12 weeks. Using lentivirus vector, mature human gut xenografts were transduced with luciferase gene under the control of 5 copies of the NF-κB response element. Two weeks thereafter, luminescence intravital imaging was performed using cooled CCD optical microscopic imaging system (IVIS Lumina Series III, PerkinElmer Inc., MA USA) and the time course of the luminescence activity before activation (blue frame in A) and after activation (red frames in A) are presented. To quantify the measured light, images were analyzed using Living Image software (version 4.4, Caliper LifeSciences, MA, USA), equal regions of interest (ROI) were defined over the subcutaneous human gut xenografts (red ellipses in A-B) and the optical signal intensity was expressed as photon flux in units of photons/s/cm²/steradian (color scale in B and bar graph in C). While no luminescence signal was observed before systemic injection of D-luciferin (time point 0 hr. in upper left panel in A and bar graph in C), steady state focal activity was visible (blue frame in A and blue bars in C) after luciferin injection (blue arrow in C). The focal activity of NF-κB was discretely activated (red frames in A and red bars in C) following systemic injection of LPS (1 mg/kg) (red arrow in C). To further verify the origin of luminescence signal, the skin above the xenograft was removed and the exposed xenograft was imaged in the live mouse (B). Representative results of one experiment out of five similar experiments.

https://doi.org/10.1371/journal.pone.0243010.g002
Discussion

NF-κB, a rapidly inducible transcription factor, is the master regulator of inflammation in all body systems and implicated in the pathogenesis of disease conditions such as human IBD [1]. Previous animal studies demonstrated that impairment of NF-κB signaling in intestinal epithelial cells resulted in inflammatory diseases. To this end, better understanding the temporal and spatial dynamics of NF-κB activity is important and these were previously analyzed in various animal models. Using transgenic mice that express luciferase under the control of NF-κB, intravital activation of NF-κB was visualized in skin, lungs, spleen, Peyer’s patches, and the wall of the small intestine at 4–5 hours following systemic treatment with TNFα, IL1α and LPS [55]. This system enabled low resolution, intravital, spatial and temporal analysis of NF-κB activity in superficial structures like skin and joints or ex-vivo snap shots of isolated organs. However, the strong signaling emanating from lymphoid tissues, Peyer’s patches, and gut parenchymal cells precluded specific analysis of NF-κB activity in gut mucosal epithelial layer. Alternatively, using transgenic mice that express enhanced green fluorescence protein (EGFP) under the control of NF-κB, enabled high resolution microscopic analysis on sections of the gut. The use of bioluminescence imaging of NF-κB in human fetal gut transplanted into SCID mice allowed for a detailed analysis of the activation of NF-κB in human gut under inflammatory conditions.

Fig 3. Spatial and temporal activity of NF-κB in steady state and inflamed human gut activated by systemic human TNFα. Human fetal gut was transplanted into two SCID mice and allowed to develop over 12 weeks. The reporter system and intravital imaging were performed as described above (see Fig 1). Time course of the luminescence activity before activation (A) and 1 (B) and 2 (C) hours after activation following systemic injection of human TNFα are presented. While no luminescence signal was observed before systemic injection of D-luciferin (-luc in A), steady state focal activity was visible in one transplant (yellow arrow in A) after luciferin injection. The focal activity of NF-κB was discretely activated following systemic injection of TNFα (1 mg/kg) (yellow and red arrows in B–C). The expression of luciferase in the human gut transplant 2 hours after activation with TNFα was imaged using immunostaining and fluorescence microscopy (D–E). Representative images of fluorescence staining of cryosections using phalloidin (D–E, blue), anti luciferase antibodies (D–E, red) and anti murine CD45 antibodies (green in E). Luciferase expression is limited to mucosal villous epithelial cells (crypts are demarcated by broken white line E). Scale bars, 100 μm (D) and 50 μm (E). Representative results of one experiment out of five similar experiments.

https://doi.org/10.1371/journal.pone.0243010.g003
These mice were systemically treated with LPS and gut sections were microscopically analyzed for EGFP fluorescence 4 and 24 hours thereafter. These authors suggested regional specificity in NF-κB responsiveness in the gut which was mostly attributed to immune cells in the lamina propria of the duodenum and proximal jejunum. Interestingly, gut epithelial cells were only sparsely activated although small foci of activated epithelial cells are visible in the published images. These observations were further supported by studies in NF-κB/EGFP transgenic zebra fish demonstrating NF-κB activation in subpopulations of intestinal epithelial cells by luminal bacteria [57].

Although technically challenging, using low resolution bioluminescence imaging and high resolution fluorescence microscopy, the above described experimental platforms can be used for intravital spatial and temporal analysis of NF-κB activity in steady state and inflamed mouse gut. Furthermore, this can be achieved in the same animal using transgenic mice co-expressing luciferase and EGFP regulated by a bidirectional NF-κB response element as previously reported [58]. Moreover, cell-specific (e.g. gut epithelial cells) co-expression of bioluminescence and fluorescence reporters can be achieved in transgenic mice using the Cre-LoxP technology.
Here, we have used the xenograft model system to study the dynamics of NF-κB in steady state and inflamed human gut. This experimental platform also enabled us to circumvent some of the above described limitations. We show here that genetic manipulation of human gut cells can be achieved using lentivirus technology and that the ectopic subcutaneous location render the transplants highly accessible for accurate viral infection, bacterial intraluminal challenge and intravital imaging. As VSV-G lentivirus infection is limited to cells expressing LDLR and is inefficient in lymphoid [34] and myeloid immune cells [59], we have found that infection and transduction were limited to the mucosal epithelial cells in the human gut xenografts. Henceforth, this lentivirus technology enabled us to transduce mucosal epithelial cells of human gut transplants with a genetic construct containing five NF-κB binding sites coupled to the gene encoding firefly luciferase. We have used this experimental platform to study the temporal and spatial dynamics of NF-κB in steady state and following systemic activation with LPS or TNFα, or intraluminal challenge with a human-specific Enteropathogenic E. coli. Surprisingly, intravital bioluminescence imaging of NF-κB activity in gut epithelial cells exposed “hotspots” representing clusters of NF-κB-activated cells. We suspected that these foci of luciferase expression might be related to inhomogeneous viral injection and transduction rates, however, luciferase gene copy number analysis was not supportive for this plausible explanation.

We have also conducted a more detailed analysis of hotspots and quiescent gut tissues using anti luciferase immunofluorescence microscopy. This extensive and exhaustive analysis of the tissues revealed three important observations; (1) luciferase expression was not detected...
in the quiescent gut tissues, (2) luciferase expression could only be detected in human gut epithelial cells and was absent from other cell types in the xenografts, including from CD45-positive immune cells, (3) luciferase expression was highly variable among epithelial cells within individual hotspots. To this end, we have noticed that Karrasch et al [60] presented confocal images of colonic sections depicting similar transient and variable NF-κB activity in intestinal epithelial cells from NF-κB/EGFP transgenic mice following bacterial colonization. Furthermore, these results are also consistent with previous animal studies demonstrating constitutive NF-κB activity in subsets of normal gut epithelial cells which are further activated by bacteria and inflammatory mediators [57]. Further work is required to better characterize NF-κB activity in distinct cell types of the intestinal epithelial interface.

Although our results cannot be directly compared with in vitro studies of NF-κB activity in other cell types, the hotspots of NF-κB activity observed in steady state xenografts might represent the highly responsive “leaky” cells reported by Patel et al. [5]. It remains an open question as to what may leads to this variation in NF-κB activity in steady state IEC, one intriguing possibility is that epigenetic variance in genes encoding for NF-κB network components enforce this variability. Indeed, epigenetic mechanisms are known to shape gene expression in ISC [61], the progenitors of all IEC, and were linked to susceptibility IBD [62]. It still remain to understand if hotspots of NF-κB activity are normal feature of the human gut or we can also speculate that epigenetic changes affecting the developing human fetal gut as subcutaneous xenografts in SCID mice might lead to the development of clusters of “leaky” epithelial cells hyper responsive to general insults. Either way both of these notions are plausible and further studies are required to elucidate the underlying cellular and molecular mechanisms involved and to understand their relevance to clinical situations in IBD patients.

Supporting information

S1 Fig. In vitro validation of the lentivirus target and reporter system. (A) demonstrating expression and transcription of luciferase using luminescence analysis (B-C) and fluorescence in situ hybridization (FISH; D-E) of luciferase (luc2CP) mRNA. Human THP-1 (B) and mouse RAW 264.7 (C) macrophage-like cell lines, were infected with the lentiviral NF-κB reporter vector (A). Cells were activated with LPS (B-C), and Mycoplasma bovis lipoproteins (D). Luminescence imaging and analysis were performed using cooled CCD optical macroscopic imaging system (B-C; IVIS Lumina Series III, PerkinElmer Inc., MA USA). FISH and nuclear staining with 4,6-diamidino-2-phenylindole (DAPI) of activated (C) and control EPH4 cells (D) demonstrating luc2CP transcripts in activated cells. Microscopic images were taken with epifluorescence microscopy system (Axio Imager M1, Zeiss, Germany). Scale bars 20 μm (C-D).

S2 Fig. In vitro validation of the lentivirus target and reporter system. Mouse mammary epithelial line EPH4 (A&C) and human embryonic cell line HEK293T (B&D) were infected with the lentiviral NF-κB reporter vector (S1A Fig). Transduced cells were infected with wild type (WT) enteropathogenic E. coli bacteria, the type 3 secretion system (T3SS)-defective mutant strain ΔescV, and ΔIE6/PP4, and ΔnleBCDE mutant strains which are defective in anti-NF-κB effectors. In EPH4 cells NF-κB pathway is activated by all bacterial strains through pathogen associated molecular patterns (PAMPs)-toll-like receptor (TLR) signalling (1 in A) and T3SS-dependent activation following infection with WT and the anti-NF-κB-defective mutant strains (2 in A). Inhibition of NF-κB activation is mediated by T3SS-dependent anti-NF-κB effectors and is limited to WT infection of EPH4 cells (3 in A). HEK293T cells are TLR signaling-defective and both activation (2 in B) and inhibition (3 in B) of NF-κB signaling is T3SS-dependent. Luminescence analysis of NF-κB activation following infection with the
above described bacterial strains were performed using SpectraMax i3x multiple detection microplate reader (Molecular Devices, CA USA) and are presented in C-D. Representative results of one experiment out of three similar experiments.

(TIF)

**S3 Fig. Lineage tracing of human intestinal stem cells (ISC) in gut xenografts.** Human fetal gut was infected with lentivirus carrying the human p65-RFP gene. Fetal gut was transplanted subcutaneously in SCID mouse and allowed to develop over 12 weeks into a mature pediatric gut. Cryosections of the gut xenograft were stained with DAPI imaged under fluorescence microscopy. The heritable genetic marker was integrated into stem cells via lentiviral vector infection, all other cells transduced by the lentivirus vector were lost in the course of xenograft development over a 12 week period. The transduced stem cells in which the p65-RFP transgene have been integrated generated progeny that produce the p65-RFP protein. These cells extend from the crypt base to the villus tip and can be visualized as ribbons of red fluorescing cells.

(TIF)

**Acknowledgments**

The authors acknowledge the technical assistance in transplantation of human fetal gut from Dr. Irit Shoval.

The authors acknowledge the scientific and technical assistance in the construction and use of the lentivirus technologies from Drs. James Bagnall and Pawel Paszek of the Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

This manuscript has been released as a pre-print at bioRxiv [63].

**Author Contributions**

**Conceptualization:** Nahum Y. Shpigel.

**Data curation:** Einat Nissim-Eliraz, Eilam Nir, Nahum Y. Shpigel.

**Formal analysis:** Einat Nissim-Eliraz, Eilam Nir, Nahum Y. Shpigel.

**Funding acquisition:** Nahum Y. Shpigel.

**Investigation:** Einat Nissim-Eliraz, Eilam Nir, Noga Marsiano, Nahum Y. Shpigel.

**Methodology:** Einat Nissim-Eliraz, Eilam Nir, Nahum Y. Shpigel.

**Project administration:** Einat Nissim-Eliraz, Nahum Y. Shpigel.

**Resources:** Simcha Yagel, Nahum Y. Shpigel.

**Supervision:** Nahum Y. Shpigel.

**Validation:** Nahum Y. Shpigel.

**Visualization:** Eilam Nir, Nahum Y. Shpigel.

**Writing – original draft:** Nahum Y. Shpigel.

**Writing – review & editing:** Einat Nissim-Eliraz, Eilam Nir, Noga Marsiano, Simcha Yagel, Nahum Y. Shpigel.

**References**

1. Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell. 2017; 168(1):37–57. https://doi.org/10.1016/j.cell.2016.12.012 PMID: 28086098
2. Atreya I, Atreya R, Neurath MF. NF-κB in inflammatory bowel disease. Journal of Internal Medicine. 2008; 263(6):591–6. https://doi.org/10.1111/j.1365-2796.2008.01953.x PMID: 18479258

3. Mikuda N, Schmidt-Ullrich R, Kärgel E, Golusda L, Wolf J, Höpken UE, et al. Deficiency in IkBα in the intestinal epithelium leads to spontaneous inflammation and mediates apoptosis in the gut. The Journal of Pathology. 2020; 251(2):160–74. https://doi.org/10.1002/path.5437 PMID: 32220243

4. Son M, Wang A, Tu H-L, Metzger MO, Patel P, Husain K, et al. Input dose differentiation by NF-κB. bioRxiv. 2019;752394. https://doi.org/10.1101/752394

5. Patel P, Drayman N, Liu P, Bilgic M, Tay S. Deep learning reveals hidden variables underlying NF-κB activation in single cells. bioRxiv. 2019;687848. https://doi.org/10.1101/687848

6. Adamson A, Boddington C, Downton P, Rowe W, Bagnall J, Lam C, et al. Signal transduction controls heterogeneous NF-κB dynamics and target gene expression through cytokine-specific refractory states. Nature Communications. 2016; 7(1):12057. https://doi.org/10.1038/ncomms12057 PMID: 27381163

7. Winter HS, Hendren RB, Fox CH, Russell GJ, Perez-Atayde A, Bhan AK, et al. Human intestine matures as nude mouse xenograft. Gastroenterology. 1991; 100(1):89–98. https://doi.org/10.1016/0016-5085(91)90587-b PMID: 1983853.

8. Nagy N, Marsiano N, Bruckner RS, Scharl M, Gutnick MJ, Yagel S, et al. Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: Novel platforms for the study of the human enteric nervous system. Neurogastroenterol Motil. 2018; 30(3). https://doi.org/10.1111/nemo.13212 PMID: 28884943; PubMed Central PMCID: PMC5823721.

9. Golan L, Gonen E, Yagel S, Rosenshine I, Shpigel NY. Enterohemorrhagic Escherichia coli induce attaching and effacing lesions and hemorrhagic colitis in human and bovine intestinal xenograft models. Disease models & mechanisms. 2011; 4(1):86–94. https://doi.org/10.1242/dmm.005777 PMID: 20959635; PubMed Central PMCID: PMC3014348.

10. Golan L, Livneh-Kol A, Gonen E, Yagel S, Rosenshine I, Shpigel NY. Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation. The Journal of Infectious Diseases. 2009; 199(3):350–4. https://doi.org/10.1086/596033 PMID: 19133807.

11. Canavan JB, Scotta C, Vossenkammer A, Goldberg R, Elder MJ, Shoval I, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn’s disease. Gut. 2016; 65 (4):584–94. https://doi.org/10.1136/gutjnl-2014-306919 PMID: 25713535; PubMed Central PMCID: PMC4819603.

12. Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, et al. Correction of Defective T-Regulatory Cells From Patients With Crohn’s Disease by Ex Vivo Ligation of Retinoic Acid Receptor-alpha. Gastroenterology. 2019; 156(6):1775–87. https://doi.org/10.1053/j.gastro.2019.01.025 PMID: 30710527.

13. Bruckner RS, Nissim-Eliraz E, Marsiano N, Nir E, Shemesh H, Leutenegger M, et al. Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. J Crohns Colitis. 2019; 13(6):798–806. https://doi.org/10.1093/ecco-jcc/jjy226 PMID: 30590414.

14. Nissim-Eliraz E, Nir E, Shoval I, Marsiano N, Nissan I, Shemesh H, et al. Type Three Secretion System-Dependent Microvascular Thrombosis and Ischemic Enteritis in Human Gut Xenografts Infected with Enteropathogenic Escherichia coli. Infection and immunity. 2017; 85(11). https://doi.org/10.1128/IAI.00558-17 PMID: 28749229; PubMed Central PMCID: PMC5649022.

15. Savidge TC, Lowe DC, Walker WA. Developmental regulation of intestinal epithelial hydrolase activity in human fetal jejunal xenografts maintained in severe-combined immunodeficient mice. Pediatr Res. 2001; 50(2):196–202. https://doi.org/10.1203/00006450-200108000-00006 PMID: 11477203.

16. Savidge TC, Morey AL, Ferguson DJ, Fleming KA, Shmakov AN, Phillips AD. Human intestinal developmental in a severe-combined immunodeficient xenograft model. Differentiation. 1995; 58(5):361–71. https://doi.org/10.1016/0012-3600(95)58510527.

17. Gaska JM, Plass A. Study of viral pathogenesis in humanized mice. Current Opinion in Virology. 2015; 11:14–20. https://doi.org/10.1016/j.civiro.2015.01.002 PMID: 25618248

18. Wahl A, De C, Abad Fernandez M, Lenarcic EM, Xu Y, Cockrell AS, et al. Precision mouse models with expanded tropism for human pathogens. Nature biotechnology. 2019; 37(10):1163–73. https://doi.org/10.1038/s41589-019-0225-9 PMID: 31451733

19. Li N, van Unen V, Abdelaat T, Guo N, Kasatskaya SA, Laddell K, et al. Memory CD4+ T cells are generated in the human fetal intestine. Nature Immunology. 2019; 20(3):301–12. https://doi.org/10.1038/s41590-018-0294-9 PMID: 30664737

20. Li N, van Unen V, Höltt T, Thompson A, van Bergen J, Pezzotti N, et al. Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine. Journal of Experimental Medicine. 2018; 215(5):1383–96. https://doi.org/10.1084/jem.20171934 PMID: 29511064
21. Rechavi E, Lev A, Lee YN, Simon AJ, Yinon Y, Liptz S, et al. Timely and spatially regulated maturation of B and T cell repertoire during human fetal development. Science Translational Medicine. 2015; 7 (276):276ra25–ra25. https://doi.org/10.1126/scitranslmed.aaa0072 PMID: 25717098

22. Stras SF, Werner L, Toothaker JM, Olaloye OO, Oldham AL, McCourt CC, et al. Maturation of the Human Intestinal Immune System Occurs Early in Fetal Development. Developmental Cell. 2019; 51 (3):357–73.e5. https://doi.org/10.1016/j.devcel.2019.09.008 PMID: 31607651

23. Schreurs RRCE, Baumdick ME, Sagedi BF, Kaufmann M, Mokry M, Klarenbeek PL, et al. Human Fetal TNF-α-Cytokine-Producing CD4+ Effector Memory T Cells Promote Intestinal Development and Mediate Inflammation Early in Life. Immunity. 2019; 50(2):462–76.e8. https://doi.org/10.1016/j.immuni.2018.12.010 PMID: 30770246

24. Gehart H, Clevers H. Tales from the crypt: new insights into intestinal stem cells. Nature Reviews Gastroenterology & Hepatology. 2019; 16(1):19–34. https://doi.org/10.1038/s41575-018-0081-y PMID: 30429586

25. Williams JM, Duckworth CA, Watson AJ, Frey MR, Miguel JC, Burkitt MD, et al. A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide. Disease models & mechanisms. 2013; 6(6):1388–99. https://doi.org/10.1242/dmm.013284 PMID: 24046352; PubMed Central PMCID: PMCPMC3820262.

26. Newton K, Dugger DL, Maltzman A, Greve HM, Martin-McNulty B, et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 2016; 23(9):1565–76. https://doi.org/10.1038/cdd.2016.46 PMID: 27120719

27. Van Hauwermeiren F, Armaka M, Karagianni N, Kranidioti K, Vandebroucke RE, Loges S, et al. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. The Journal of clinical investigation. 2013; 123(6):2590–603. https://doi.org/10.1172/JCI65624 PMID: 23764645

28. Guma M, Stepiak D, Shaked H, Spehlmann ME, Shenouda S, Cheroutre H, et al. Constitutive intestinal NF-κB does not trigger destructive inflammation unless accompanied by MAPK activation. The Journal of Experimental Medicine. 2011; 208(9):1889–900. https://doi.org/10.1084/jem.20110242 PMID: 21825016

29. Vereecke L, Sze M, Guire CM, Rogiers J, Chu Y, Schmidt-Supprian M, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor–induced toxicity and experimental colitis. The Journal of Experimental Medicine. 2010; 207(7):1513–23. https://doi.org/10.1084/jem.20092474 PMID: 20530205

30. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, et al. Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter. Journal of Biological Chemistry. 1998; 273(52):34970–5. https://doi.org/10.1074/jbc.273.52.34970 PMID: 9857028

31. Suter DM, Molina N, Gatfield D, Schneider K, Schibler U, Naef F. Mammalian Genes Are Transcribed with Widely Different Bursting Kinetics. Science. 2011; 332(6028):472–4. https://doi.org/10.1126/science.1198817 PMID: 21415320

32. Brignall R, Cauchy P, Bevington SL, Gorman B, Pisco AO, Brignall J, et al. Integration of Kinase and Calcium Signaling at the Level of Chromatin Underlies Inducible Gene Activation in T Cells. The Journal of Immunology. 2017; 199(6):2652–67. https://doi.org/10.4049/jimmunol.1602033 PMID: 28904128

33. Bagnall J, Dodington B, Boyd J, Brignall R, Rowe W, Jones NA, et al. Quantitative dynamic imaging of immune cell signalling using lentiviral gene transfer. Integrative Biology. 2015; 7(6):713–25. https://doi.org/10.1039/c5ib00067j PMID: 25990200

34. Amirache F, Levy C, Costa C, Mangeot PE, Torbett BE, Wang CX, et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood. 2014; 123(9):1422–4. https://doi.org/10.1182/blood-2013-11-540641 PMID: 24578496

35. Finkelstein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(18):7306–11. https://doi.org/10.1073/pnas.1214441110 PMID: 23589850; PubMed Central PMCID: PMC3645523.

36. Girard-Gagnepain A, Amirache F, Costa C, Levy C, Frecha C, Fusil F, et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood. 2014; 124(8):1221–31. https://doi.org/10.1182/blood-2014-02-558163 PMID: 24951430.

37. Salamon H, Nissim-Elizar E, Ardonai O, Nissan I, Shigel NY. The role of O-polysaccharide chain and complement resistance of Escherichia coli in mammary virulence. Veterinary Research. 2020; 51 (1):77. https://doi.org/10.1186/s13567-020-00804-x PMID: 32539761

38. Mintz M, Mintz D, Ilia-Ezra R, Shigel NY. Pam3CSK4/TLR2 signaling elicits neutrophil recruitment and restricts invasion of Escherichia coli P4 into mammary gland epithelial cells in a murine mastitis model.
Veterinary immunology and immunopathology. 2013; 152(1–2):168–75. https://doi.org/10.1016/j.vetimm.2012.09.030 PMID: 23073139.

39. Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, et al. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. The EMBO journal. 2011; 30(1):221–31. https://doi.org/10.1038/emboj.2010.297 PMID: 21113130; PubMed Central PMCID: PMC3020117.

40. Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Meth. 2008; 5(10):877–9. http://www.nature.com/nmeth/journal/v5/n10/supplinfo/nmeth.1253_S1.html.

41. Lysnyansky I, Freed M, Rosales RS, Mikula I, Khateb N, Gerchman I, et al. An overview of Mycoplasma bovis mastitis in Israel (2004–2014). The Veterinary Journal. 2016; 207:180–3. https://doi.org/10.1016/j.tvjl.2015.10.057 PMID: 26626090.

42. Elkind E, Vaisid T, Koranspa JD, Barnoy S, Rottem S, Kosower NS. Calpastatin upregulation in Mycoplasma hyorhinis-infected cells is promoted by the mycoplasma lipoproteins via the NF-kappaB pathway. Cell Microbiol. 2012; 14(6):840–51. https://doi.org/10.1111/j.1462-5822.2012.01760.x PMID: 22288381.

43. Salguero G, Daenthanasanmak A, Münz C, Raykova A, Guzmán CA, Riese P, et al. Dendritic Cell–Mediated Immune Humanization of Mice: Implications for Allogeneic and Xenogeneic Stem Cell Transplantation. The Journal of Immunology. 2014; 192(10):4636–47. https://doi.org/10.4049/jimmunol.1302887 PMID: 24740501.

44. Prescher JA, Contag CH. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Current Opinion in Chemical Biology. 2010; 14(1):80–9. https://doi.org/10.1016/j.cbpa.2009.11.001 PMID: 19962933.

45. Evans MS, Chaurette JP, Adams ST, Reddy GR, Paley MA, Aronin N, et al. A synthetic luciferin improves bioluminescence imaging in live mice. Nature Methods. 2014; 11(4):393–5. https://doi.org/10.1038/nmeth.2839 PMID: 24509630.

46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–8. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609.

47. Kohn DB, Hollis RP. Envelope, please. And the award goes to. Blood. 2014; 124(8):1203–4. https://doi.org/10.1182/blood-2014-06-583823 PMID: 25147372; PubMed Central PMCID: PMC4141502.

48. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier E, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013; 227(2):297–306. https://doi.org/10.1016/j.atherosclerosis.2013.01.023 PMID: 23422832.

49. Pathak RK, Yokode M, Hammer RE, Hofmann SL, Brown MS, Goldstein JL, et al. Tissue-specific sorting of the human LDL receptor in polarized epithelia of transgenic mice. The Journal of cell biology. 1990; 111(2):347–59. https://doi.org/10.1083/jcb.111.2.347 PMID: 21996458; PubMed Central PMCID: PMC2116187.

50. Fong LG, Bonney E, Kosek JC, Cooper AD. Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine. The Journal of clinical investigation. 1989; 84(3):847–56. https://doi.org/10.1172/jci112445 PMID: 2760216; PubMed Central PMCID: PMC329728.

51. Meoli L, Ben-Zvi D, Panciotti C, Kvas S, Pizarro P, Munoz R, et al. Intestine-Specific Overexpression of LDLR Enhances Cholesterol Excretion and Induces Metabolic Changes in Male Mice. Endocrinology. 2018; 160(4):744–58. https://doi.org/10.1210/en.2018-00096.2012 PMID: 23335792.

52. Chen Y, Ruan XZ, Li Q, Huang A, Moorhead JF, Powis SH, et al. Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells. American journal of physiology Renal physiology. 2007; 293(3):F680–7. https://doi.org/10.1152/ajprenal.00209.2007 PMID: 17634396.

53. Li LC, Varghese Z, Moorhead JF, Lee CT, Chen JB, Ruan XZ. Cross-talk between TLR4-MyD88-NF-kappaB and SCAP-SREBP2 pathways mediates macrophage foam cell formation. American journal of physiology Heart and circulatory physiology. 2013; 304(6):H874–84. https://doi.org/10.1152/ajpheart.00096.2012 PMID: 23356592.

54. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Science Translational Medicine. 2014; 6(258):258ra143. https://doi.org/10.1126/scitranslmed.3008782 PMID: 25320235.

55. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappaB activity. J Immunol. 2002; 168(3):1441–6. https://doi.org/10.4049/jimmunol.168.3.1441 PMID: 11801687.

56. Magness ST, Jijn H, Van Houten Fisher N, Sharpless NE, Brenner DA, Jobin C. In Vivo Pattern of Lipopolysaccharide and Anti-CD3-Induced NF-κB Activation Using a Novel Gene-Targeted Enhanced GFP Reporter Gene Mouse. The Journal of Immunology. 2004; 173(3):1561–70. https://doi.org/10.4049/jimmunol.173.3.1561 PMID: 15265883.
57. Kanther M, Sun X, Mühlbauer M, Mackey LC, Flynn III EJ, Bagnat M, et al. Microbial Colonization Induces Dynamic Temporal and Spatial Patterns of NF-κB Activation in the Zebrafish Digestive Tract. Gastroenterology. 2011; 141(1):197–207. https://doi.org/10.1053/j.gastro.2011.03.042 PMID: 21439961

58. Kielland A, Camassa LMA, Døhlen G, Munthe LA, Blomhoff R, Amiry-Moghadam M, et al. NF-κB Activity in Perinatal Brain During Infectious and Hypoxic-Ischemic Insults Revealed by a Reporter Mouse. Brain Pathology. 2012; 22(4):499–510. https://doi.org/10.1111/j.1750-3639.2011.00548.x PMID: 22059637

59. Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Science Translational Medicine. 2019; 11(493): eaav7325. https://doi.org/10.1126/scitranslmed.aav7325 PMID: 31118293

60. Karrasch T, Kim J-S, Mühlbauer M, Magness ST, Jobin C. Gnotobiotic IL-10−/−;NF-κBEGFP Mice Reveal the Critical Role of TLR/NF-κB Signaling in Commensal Bacteria-Induced Colitis. The Journal of Immunology. 2007; 178(10):6522–32. https://doi.org/10.4049/jimmunol.178.10.6522 PMID: 17475882

61. Hu D, Yan H, He X, Li L. Recent advances in understanding intestinal stem cell regulation [version 1; peer review: 3 approved]. F1000Research. 2019; 8(72). https://doi.org/10.12688/f1000research.16793.1 PMID: 30705753

62. Howell KJ, Kriczy J, Nayak KM, Gasparetto M, Ross A, Lee C, et al. DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome. Gastroenterology. 2018; 154(3):585–98. https://doi.org/10.1053/j.gastro.2017.10.007 PMID: 29031501; PubMed Central PMCID: PMC6381389.

63. Nissim-Eliraz E, Nir E, Marsiano N, Yagel S, Shpigel NY. NF-kappa-B activation unveils the presence of inflammatory hotspots in human gut xenografts. bioRxiv. 2020:2020.07.23.212621. https://doi.org/10.1101/2020.07.23.212621